Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis

Hubertus Rosery; Rito Bergemann; Steven E. Marx; Axel Boehnke; Joel Melnick; Raimund Sterz; Laura Williams


Clin Drug Invest. 2006;26(11):629-638. 

In This Article

5. Conclusion

This analysis suggests a clear benefit of intravenous paricalcitol with respect to costs, effectiveness and utilities compared with oral calcitriol and intravenous alfacalcidol in the treatment of patients with secondary hyperparathyroidism from the perspective of a third-party payer. Since direct comparative studies are not available, some assumptions were made in this analysis, which was based on results of historical cohort studies. Therefore, further investigation is required to verify the appropriateness of these assumptions.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.